About: Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. From April 2004 to August 2008,. of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%). We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. From April 2004 to August 2008,. of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%). (en)
Title	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia (en)
skos:prefLabel	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia (en)
skos:notation	RIV/00216208:11130/10:6264!RIV11-MZ0-11130___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NS9997), Z(MZ0FNM2005)
http://linked.open...iv/cisloPeriodika	19
http://linked.open...vai/riv/dodaniDat	2011
http://linked.open...aciTvurceVysledku	Kabíčková, Edita
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 2. lékařská fakulta
http://linked.open...dnocenehoVysledku	278725
http://linked.open...ai/riv/idVysledku	RIV/00216208:11130/10:6264
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	acute-lymphoblastic-leukemia; chemotherapy plus rituximab; randomized controlled-trial; childrens oncology group; central-nervous-system; elderly-patients; induced apoptosis; clinical-trials; r-chop; adolescents (en)
http://linked.open.../riv/klicoveSlovo	induced apoptosis central-nervous-system clinical-trials randomized controlled-trial adolescents elderly-patients acute-lymphoblastic-leukemia chemotherapy plus rituximab r-chop childrens oncology group
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[4D2B363A1AD8]
http://linked.open...i/riv/nazevZdroje	Journal of Clinical Oncology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	14 (xsd:int)
http://linked.open...vavai/riv/projekt	Optimization of anticancer treatment for childhood lymphomas based on integration of PET (FDG-PET, FDG-PET/CT) into treatment planning and monitoring
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	28
http://linked.open...iv/tvurceVysledku	Kabíčková, Edita Zimmermann, M. Burkhardt, B. Klapper, W. Reiter, A. Borkhardt, A. Klingebiel, T. Schrappe, M. Attarbaschi, A. Berthold, F. Janka-Schaub, G. Klein, C. Kontny, U. Meinhardt, A.
http://linked.open...ain/vavai/riv/wos	000279254300005
http://linked.open...n/vavai/riv/zamer	Zdokonalení časné diagnostiky, prevence a léčby těžkých vrozených vývojových vad a chorob geneticky podmíněných či s genetickou dispozicí v prenatální a postnatální fázi vývoje
issn	0732-183X
number of pages	7 (xsd:int)
http://localhost/t...ganizacniJednotka	11130
is http://linked.open...avai/riv/vysledek of	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software